Please wait while the formulary information is being retrieved.
NUPLAZID (pimavanserin tartrate)
- Psychosis associated with parkinson's disease
10 mg tablet
- 1 tablet (10 mg) by oral route once daily
34 mg capsule
- 1 capsule (34 mg) by oral route once daily
Psychosis associated with parkinson's disease
- 1 tablet (10 mg) by oral route once daily
- 1 capsule (34 mg) by oral route once daily
- None
Contraindicated
- Geodon
- ziprasidone HCl
- ziprasidone mesylate
Severe
Moderate
- None
- Congenital long QT syndrome
- Senile dementia with psychosis
Contraindicated
- Bradycardia
- Hypokalemia
- Hypomagnesemia
- Pregnancy
Severe
Moderate
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Kidney disease with likely reduction in GFR
NUPLAZID (pimavanserin tartrate)
- Psychosis associated with parkinson's disease
- None
- Acute confusion
- Peripheral edema
More Frequent
Severe
Less Severe
- None
- Constipation
- Fatigue
- Gait abnormality
- Nausea
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Accidental fall
- Angioedema
- Circumoral edema
- Prolonged QT interval
- Throat constriction
- Tongue swelling
- Urticaria
Less Severe
- Aggressive behavior
- Agitation
- Drowsy
- Dyspnea
- Hallucinations
- Skin rash
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pimavanserin
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Pimavanserin
- Severity Level:
D
- Additional Notes: Insuff human data; potential for serious adv effects; animal data sugg dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pimavanserin
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Pimavanserin
Cardiovascular-Risk of QT prolongation. Avoid use with underlying cardiac arrhythmia. Endocrine-May exacerbate or cause SIADH or hyponatremia. Renal-Not recommended with CrCL < 30 mL/min Neuro/Psych-Not intended for hallucinations associated with senile dementia. Avoid use for behavioral problems of dementia or delirium unless failed nonpharm options. Increased risk of stroke, cognitive decline, and death when used with senile dementia.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | Y | N | Y |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- There may be a slightly increased risk of serious, possibly fatal side effects (such as stroke, heart failure, fast/irregular heartbeat, pneumonia) when this medication is used by older adults with dementia. This medication should only be used to treat a certain mental/mood disorder (psychosis) due to Parkinson's disease. Talk with the doctor about the risks and benefits of treatment with this medication.
| Psychosis associated with parkinson's disease | |
| F06.0 | Psychotic disorder with hallucinations due to known physiological condition |
| F06.2 | Psychotic disorder with delusions due to known physiological condition |
| G20 | Parkinson's disease |
| 0-9 | A-Z |
|---|---|
| F06.0 | Psychotic disorder with hallucinations due to known physiological condition |
| F06.2 | Psychotic disorder with delusions due to known physiological condition |
| G20 | Parkinson's disease |
Formulary Reference Tool